Bearer of Hope and Impulse
Interview with Dr. Charles Mamisch, Managing Director of MedTec Medizintechnik GmbH
Osteoporosis and arthritis are degenerative diseases that increase with age. In light of demographic changes, preventative measures that slow down bone loss and joint wear are becoming increasingly important. MedTec Medizintechnik GmbH has developed a non-invasive, gentle, and effective treatment method with MBST nuclear magnetic resonance technology, which combines scientific expertise and medical engineering – offering patients hope for a better quality of life.
Wirtschaftsforum: Dr. Mamisch, you are the CEO of a company that sets new standards in medical technology with MBST technology. What exactly does MBST mean?
Dr. Charles Mamisch: MBST therapy is a therapeutic development based on the nuclear spin technology used for three-dimensional representations of body layers. Our technology does not use nuclear spin technology to create images, but rather to initiate specific processes in organic tissue. An energy transfer occurs; with the help of electromagnets and radio waves, various metabolic processes can be initiated. The therapy can stimulate body cells and promote their regeneration. Initially, this affects cartilage or bone cells, which cause pain in conditions such as arthrosis or osteoporosis. Depending on the degree of degeneration, the cellular treatment can lead to rapid pain relief.
Wirtschaftsforum: With this scientifically based technology, MedTec has caused an international sensation. The company has received many awards and prizes and has repeatedly been among the top 100 most innovative SMEs in Germany. What is the story behind this success?
Dr. Charles Mamisch: MedTec was founded in 1998 by Axel Muntermann in Wetzlar and from the beginning focused on the therapeutic use of MBST nuclear magnetic resonance technology. Since 2022, the company has been part of the Swedish Lifco, a group of around 280 independently operated SMEs. We have 23 employees and collaborate closely with universities and research institutions. The combination of medical technology expertise and engineering is a hallmark of MedTec and is reflected in our devices.
Wirtschaftsforum: The devices represent the highest quality standards. How can MedTec guarantee this quality?
Dr. Charles Mamisch: Development and production take place exclusively in Germany. We develop the devices, and external partners manufacture them. After production, the devices come back to us, where we perform the final assembly and thoroughly test the devices. Part of our quality management includes certification according to DIN EN ISO 13485 and the EU Medical Device Regulation 2017/45 (MDR).
Wirtschaftsforum: The MedTec devices stand not only for certified quality, but also for effectiveness. How can one imagine that?
Dr. Charles Mamisch: The therapy initiates certain cellular processes, allowing cells to regenerate. In osteoporosis, this can increase bone density, muscle injuries heal faster, inflammations subside more quickly, and recovery times can be shortened in sports injuries. Usually, seven to ten sessions are necessary; after three sessions, an improvement can already be felt as the cell structure has slowly built up. The positive effects can last a year, and in some cases, even three to five years. For sustained success, patients should undergo accompanying physiotherapy.
Wirtschaftsforum: Who works with MBST devices?
Dr. Charles Mamisch: The therapy is used in doctors' offices, health centers, hospitals, and clinics, varying from country to country. In Germany, orthopedists use the therapy, in Spain physiotherapists do, and in the United Kingdom, it's a mix of both. The German market is complex; here we have 200 centers, but they only use one to two devices each. In Spain, there are 45 centers, each of which has up to six machines available.
Wirtschaftsforum: Developed in Germany, used worldwide. Which markets could become interesting for MedTec in the future?
Dr. Charles Mamisch: China and the United Arab Emirates offer promising opportunities. In the Emirates, there is pronounced health tourism, and in China, preventative medicine plays a central role.
Wirtschaftsforum: How do you assess future market opportunities?
Dr. Charles Mamisch: Medical technology remains largely unaffected by market fluctuations and crises; moreover, we live in an aging society, where our devices are becoming increasingly important. An essential asset is therapy cards, which can be loaded with various programs tailored to different types of tissue and body regions. By analyzing cell resonances, we can adapt programming cards to individual cell regeneration with the aim to halt degenerations. There is a specially programmed card for each treatment. In the future, we would like to extend our experience and expertise to more markets and areas. It is a unique non-invasive therapy that is consistently oriented towards research and has great potential. This excites us all.